1-13 of 13
Raluca Verona
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Clinical Trials & Observations
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred Garfall
Journal: Blood
Blood blood.2023023616.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Tatiana Perova, Onsay Lau, Cuc Davis, Yue Guo, Xin Miao, Tara Stephenson, Caroline Hodin, Clarissa Uhlar, Danielle Trancucci, Katherine Chastain, Nizar J Bahlis, Niels W.C.J. Van De Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 455.
https://doi.org/10.1182/blood-2023-173550
Published: 2023
Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2023-187755
Published: 2023
Journal Articles

Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment

Jia Zhou, Deeksha Vishwamitra, Yue Guo, Raluca Verona, Alfredo Perales Puchalt, Tara Stephenson, Caroline Hodin, Arnob Banerjee, Katherine Chastain, Nahor Haddish-Berhane, Weirong Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4670.
https://doi.org/10.1182/blood-2023-180208
Published: 2023
Journal Articles

Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells

Dennis J Wu, Amy S Chen, Nikki Deangelis, Diana Cortes, Jose Morachis, Benjamin Titz, Sylvaine Cases, Raluca Verona, Chorom Pak
Journal: Blood
Blood (2023) 142 (Supplement 1): 3659.
https://doi.org/10.1182/blood-2023-190245
Published: 2023
Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, Raluca Verona
Journal: Blood
Blood (2022) 140 (Supplement 1): 241–243.
https://doi.org/10.1182/blood-2022-162709
Published: 2022
Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Raluca Verona, Lixia Pei, Yaming Su, Daniele Ouellet, Alfred L. Garfall, Amrita Y. Krishnan, Saad Usmani, Suzette Girgis, Honghui Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 4382–4383.
https://doi.org/10.1182/blood-2022-162859
Published: 2022
Journal Articles

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7253–7254.
https://doi.org/10.1182/blood-2022-162856
Published: 2022
Journal Articles

Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples

Katherine Li, David Barnidge, Maria Krevvata, Mark C. Perkins, Raluca Verona, Enrique Zudaire
Journal: Blood
Blood (2022) 140 (Supplement 1): 12446–12447.
https://doi.org/10.1182/blood-2022-160249
Published: 2022
Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27.
https://doi.org/10.1182/blood-2020-138831
Published: 2020
Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-133873
Published: 2020
Journal Articles

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Christie P.M. Verkleij, MD, Marloes Broekmans, Amy Wong, Sonja Zweegman, MDPhD, Raluca Verona, PhD, Homer Adams, III, PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-141187
Published: 2020
Journal Articles

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Enrique Zudaire, PhD, Deepu Madduri, MD, Saad Z. Usmani, MD FACP, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD, Dong Geng, Syed Rizvi, MD, Tonia Nesheiwat, Jordan M Schecter, MD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Alicia J. Allred, PhD, Indrajeet Singh, PhD, Raluca Verona, PhD, Ian McCaffery, PhD, Sundar Jagannath
Journal: Blood
Blood (2019) 134 (Supplement_1): 928.
https://doi.org/10.1182/blood-2019-127309
Published: 2019